B+
Bull case
25%
Probability
Target price
$136.00
-1.9% vs current
BLLN
BillionToOneBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-08-01
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$112.00
-19.2% vs current
B-
Bear case
30%
Probability
Target price
$92.00
-33.6% vs current
AI sentiment snapshot
Latest data as of 2026-07-01
Recent news sentiment (30D)
+28.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
+28.0
Positive
Sentiment proxy
+25.4
Score
AI commentary
Primary-source tone is positive, driven by the May 6 results/guidance raise and the June 29 capacity update, but market enthusiasm appears partly priced in given the anchor price versus the packet target summary. Recent headlines are constructive rather than euphoric, social coverage is unavailable, and the deterministic prior remains negative, so this reads more like a cautious monitoring name than a fresh high-conviction momentum long.
RankAlpha Sentiment Codex - 2026-07-01
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15catalystQ1 beat, raised 2026 guidance, and profitability reset near-term expectationsHigh impact
Q1 revenue rose 84% to $108.4M, gross margin reached 73%, operating income turned positive at $17.8M, and full-year 2026 revenue guidance was raised to $450M-$465M with management expecting profitability near current levels [#SEC-8K-2026-05-06].
2026-12-31catalystVolume and payer expansion can extend the prenatal-plus-oncology growth flywheelHigh impact
Q1 tests delivered increased 44%, ASP rose 28%, oncology testing revenue grew more than fourfold, and management said payer contracts reached $300M contracted lives in the U.S., supporting continued adoption if execution holds [#SEC-8K-2026-05-06].
2027-03-31catalystNew lab capacity supports multi-year test-volume scalingMedium impact
A June 2026 8-K said newly leased space is intended to provide additional laboratory capacity because total test volumes exceeded plan over the last year, which supports the case for sustained throughput growth but also raises the bar for utilization [#8-K-2026-06-29].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-01 • Updated nightlySource: Internal modelMethodology